Sarah Jessica Parker Cut Ties With EpiPen Maker Mylan (MYL)

Posted on

After the price of an EpiPen shot up from $100 in 2009 all the way to almost $600, Sarah Jessica Parker has said enough is enough.

The former “Sex and the City” actress is cutting ties with Mylan, the company behind the EpiPen.

Parker’s 13-year-old son James has a severe peanut allergy and has said that the pen is a “vital part of our families healthcare as it is for many who are at risk.”

EpiPen auto injectors contain the hormone epinephrine which is used to fight off the potentially fatal allergic reaction known as anaphylactic shock.

Parker explained her decision to walk away from Mylan in an Instagram post:

“I recently learned that the price of EpiPen has been systematically raised by Mylan to a point that renders the medication cost-prohibitive to most people,” Parker wrote.

“I’m left disappointed, saddened and deeply concerned by Mylan’s actions. I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.”

“I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it is a life-saving necessity.”

Hillary Clinton has also called the price hike “outrageous.”

Disclaimer: We have no position in Mylan Inc. (NASDAQ: MYL) and have not been compensated for this article.